QLIFE HOLDING AB, Interim Report Q2, April to June 2024
QLIFE HOLDING AB faced financial and legal challenges in Q2 2024, including a significant net loss and arbitration loss against Aidian Oy, leading to bankruptcy filing for its Danish subsidiary. Despite these, operational progress was noted, including CRP biomarker trials in China and participation in a PKU research trial in the USA. The company aims to restructure and focus on the home-hospital segment and rare diseases.
Reference News
QLIFE HOLDING AB faced financial and legal challenges in Q2 2024, including a significant net loss and arbitration loss against Aidian Oy, leading to bankruptcy filing for its Danish subsidiary. Despite these, operational progress was noted, including CRP biomarker trials in China and participation in a PKU research trial in the USA. The company aims to restructure and focus on the home-hospital segment and rare diseases.